An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination with Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
MD Anderson Study Status
Avasopasem (GC4419), Placebo
The purpose of the phase I/II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with Avasopasem (GC4419) or placebo to patients who have been diagnosed with locally advanced pancreatic cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Pancreatic Cancer, Stereotactic Body Radiation Therapy
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.